Earnings Analysis November 1, 2026

Sanofi ADR ($SNY) Q3 2026 Earnings Analysis: Beat Expectations, Annual Guidance Raised

Earnings Report

Revenue: €14.444 billion (Q3 2026, approx. $16.6 billion) · +16.2% YoY · Expected $13.267 billion ✅ Beat

EPS (Earnings Per Share): €3.55 on an adjusted basis (Q3 2026, approx. $2.04 on an ADR basis) · Expected $1.51 ✅ Beat

Guidance: Upward revision · 2026 revenue growth in the low teens, adjusted EPS growth in the mid-teens (at constant exchange rates)

Stock Reaction: +2.8% (Based on BMO closing price on the same day)

Highlights

Dupixent: Q3 revenue of €5.687 billion, up 34.8% YoY

New Product Launches: Revenue from newly launched medicines reached €1.39 billion, up 31.4%

Cost Management: SG&A expenses decreased by 0.9% (at constant exchange rates), adjusted operating margin of 37.6%

There was a clear regional divergence, with U.S. revenue increasing by 23.9% while European revenue decreased by 0.9%. Increased gross profit and operating leverage drove adjusted operating income up by 22.2%, though this was partially offset by increased costs due to expanded profit sharing with Regeneron.

Lowlights

Vaccines: Q3 revenue of €3.185 billion, down 6.6% YoY

Beyfortus: €631 million, down 15.4%, with U.S. revenue down 39.3%

Net Income: €3.021 billion, a 7.8% increase, falling short of the adjusted basis (20.0%)

The decline in central orders from the U.S. Centers for Disease Control and Prevention (CDC) was directly reflected in Beyfortus revenue. Flu vaccine deliveries are concentrated in the fourth quarter, making the quarterly figures appear weak.

Management Commentary

CEO Belén Garijo explained that new medicines and Dupixent drove revenue, while cost management boosted adjusted EPS. The company stated that its top priority is to defend earnings for 10 years following the Dupixent patent expiry, which it plans to supplement through improved R&D productivity and M&A.

Market Reaction and Future Key Points

Both revenue and operating profit exceeded expectations, and the company also raised its annual guidance. The market reacted positively to both the earnings results and the upward revision of the outlook.

It is a point to monitor whether vaccine segment revenue rebounds as flu vaccine deliveries concentrate in the fourth quarter.

It remains to be seen whether the effect of price adjustments that drove Dupixent's US sales will continue into the next quarter.

It is necessary to check how the $1 billion upfront payment to Regeneron and the up to $7 billion in milestones will be reflected in costs.